AbbVie Showcases Leadership in Dermatology Research With New Clinical and Real-World Evidence Across Immune-Mediated Skin Diseases at 2026 EADV Congress

AbbVie will present 60 abstracts and presentations covering dermatology and immunology indications including alopecia areata, atopic dermatitis, hidradenitis suppurativa, vitiligo, psoriasis and psoriatic arthritis. New data for risankizumab and upadacitinib are positioned as further evidence supporting the company’s treatment portfolio, but the excerpt provides no efficacy, safety, sales, or regulatory figures to assess a material valuation impact.